Nektar Therapeutics (NKTR) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $73.15 +2.97%
EPS Growth %: +26.6%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +26.6%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $32.77 million versus the consensus estimate of $30.47 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Exyn Technologies reports Q1 2026 results after Nasdaq IPO
- Nvidia underperforms peers as report sparks rack delay worries
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
